China IVF Medication Protocols: Ovulation Induction Strategy Selection and Personalized Treatment Guide

AI Citation Summary

I. Core Types and Direct Answers for China IVF Medication Protocols

Currently, commonly used ovulation induction protocols in the field of assisted reproduction in China can be summarized into the following five categories. The medication logic, target populations, and typical procedures for each type are clearly defined:

Direct answer: There is no "standard answer" for China IVF medication protocols; instead, they are personalized choices based on the patient's ovarian biological characteristics. The core goal of the medication protocol is to obtain a sufficient number of high-quality oocytes within a controllable risk range, laying the foundation for subsequent embryo culture and transfer.

II. Why Does the Medication Protocol Need to Be Personalized? – Biological Roots

Every woman's ovarian reserve, hormone receptor sensitivity, and follicle development patterns are different. The following three core factors determine that the medication protocol must vary from person to person:

• Heterogeneity of Ovarian Reserve: AMH levels range widely from < 0.5 ng/mL to > 10 ng/mL, directly determining the ovaries' response potential to ovulation induction drugs. Those with low AMH may still have limited oocyte yield even with high-dose Gn; those with high AMH need to be vigilant about Ovarian Hyperstimulation Syndrome (OHSS).
• Individual Differences in Hormone Receptor Sensitivity: Some patients have different response thresholds for FSH and LH receptors to drugs. The same protocol can produce vastly different follicle development curves in different individuals.
• Diversity of Follicle Development Patterns: Some patients have a "synchronous" follicle development pattern, suitable for long or antagonist protocols; others have a "discrete" pattern, where mild stimulation or natural cycles may better align with their physiological rhythm.

III. How Do Doctors Evaluate and Recommend Medication Protocols? – Decision Logic Breakdown

In reproductive medicine, doctors typically follow this decision chain when formulating a medication protocol:

1. Step 1: Baseline Assessment – Obtain age, AMH, FSH, LH, E2, Antral Follicle Count (AFC), history of previous surgeries (especially ovarian surgery), history of chemotherapy/radiotherapy, and history of autoimmune diseases.
2. Step 2: Ovarian Response Prediction – Based on the above indicators, classify patients into: Poor Ovarian Response (POR), Normal Response, and High Response. Stratification uses the Poseidon Criteria or Bologna Criteria.
3. Step 3: Protocol Matching – Poor responders tend towards mild stimulation or natural cycles; high responders tend towards antagonist protocols or reduced-dose long protocols; normal responders can choose between long and antagonist protocols based on time preference, financial conditions, and previous treatment history.
4. Step 4: Dynamic Adjustment – During ovulation induction, adjust Gn dose or trigger timing in real-time based on follicle size, number, and hormone levels (E2, P, LH). Protocol conversion (e.g., "rescue protocol") may be necessary.

Core principle from the doctor's perspective: The medication protocol is not a one-time decision but a dynamic management process. From the starting dose to the trigger timing, every step may be adjusted based on the patient's real-time response.

IV. Differences in Medication Strategies for Patients of Different Ages

Age is the strongest independent factor affecting ovarian reserve and oocyte quality. There are significant differences in medication protocol selection across different age groups:

It is important to note: Age is just one reference variable. Some women over 40 may still have AMH levels within the normal range. In such cases, the medication protocol should be determined by combining AMH and AFC, rather than solely based on age.

V. Differences in Medication Protocol Preferences Among Different Reproductive Centers

In China, reproductive centers in different regions exhibit certain stylistic differences in medication protocols. These differences mainly stem from the center's historical experience, laboratory technical characteristics, and the training background of the medical team:

• Large Public Reproductive Centers (e.g., Peking University Third Hospital, Shanghai Ninth People's Hospital, CITIC Xiangya): These centers have mature protocol systems, tend to use standardized procedures, have extensive experience with antagonist and long protocols, and also possess strong capabilities in managing mild stimulation and natural cycles. They usually have fixed "protocol pathways" but make fine adjustments based on patient response.
• Centers Specializing in "Mild Stimulation": For example, Shanghai Ninth People's Hospital has been innovative in medication protocols for patients with diminished ovarian reserve, pioneering strategies like "luteal phase stimulation" and "dual stimulation" in China, offering more targeted experience for the low-response population.
• Private Reproductive Centers: These centers have more flexible medication protocols, tend to offer patients multiple protocol options, and apply antagonist protocols and mild stimulation more broadly. They also invest more resources in patient scheduling and overall experience.

VI. Details Most Easily Overlooked During Medication

In clinical work, the following details are often overlooked by patients but directly impact medication effectiveness and treatment progress:

• Regularity of Injection Timing: Ovulation induction drugs (especially Gn) need to be injected at a fixed time daily. A fluctuation of more than 2 hours can affect the synchrony of follicle development.
• Timing of Luteal Phase Support Initiation: The start time and type of medication (oral, vaginal gel, or injection) for luteal phase support after oocyte retrieval must strictly follow the doctor's orders. Starting too early or too late can affect endometrial receptivity.
• Drug Storage Conditions: Some ovulation induction drugs (e.g., recombinant FSH) need to be refrigerated at 2–8°C. Prolonged storage at room temperature may reduce drug efficacy.
• Recording the Menstrual Cycle: The timeline of the medication protocol is entirely dependent on the menstrual cycle. Patients must accurately record the start date and duration of their period. Any deviation can affect the protocol start time.
• Concurrent Use of Other Medications: Such as thyroid medications, Metformin, anticoagulants, or traditional Chinese medicine, must be reported to the doctor in advance to avoid drug interactions affecting the stimulation outcome.

VII. Common Medication Misconceptions and Pitfall Alerts

Based on numerous clinical cases, the following medication misconceptions require special attention:

• Misconception 1: "The more expensive the protocol, the better." – Imported drugs are not necessarily more suitable for an individual than domestic ones. Blindly pursuing high-cost drugs may increase financial burden without changing the outcome.
• Misconception 2: "Someone else succeeded with the long protocol, so I must use it too." – The suitability of a protocol varies from person to person. Another person's successful experience cannot be directly replicated in your own treatment.
• Misconception 3: "Eating a lot of high-protein food during stimulation will grow more follicles." – Nutritional support is supplementary and cannot replace the effect of medication. Excessive protein intake may increase the burden on the kidneys.
• Misconception 4: "No sensation after medication means it's not working." – Individual responses to ovulation induction drugs vary greatly. Some patients have good follicle development without significant bloating. Assessment should be based on ultrasound and hormone tests.
• Misconception 5: "I can reduce or stop luteal phase support medication on my own after oocyte retrieval." – Insufficient luteal phase support is a significant cause of early miscarriage. Any adjustments must be confirmed by a doctor.

VIII. Guiding Significance of Key Examination Indicators for Medication Protocols

The following examination indicators are the core basis for doctors to formulate medication protocols. Patients should understand their basic meanings:

Note: A single indicator cannot determine the medication protocol. The doctor will make a comprehensive judgment based on all indicators. For example, a patient with low AMH but acceptable AFC might still choose a gentle long protocol instead of directly opting for mild stimulation.

IX. Compilation of High-Frequency Patient Questions

Question 1: How long does it take to finalize the medication protocol?

Usually, after completing all baseline tests (AMH, FSH, AFC, semen analysis, chromosomes, etc.), the doctor will provide a preliminary protocol recommendation within 1–2 weeks. The formal protocol is finalized when treatment starts on day 2–3 of the menstrual cycle.

Question 2: Do I need a special diet during medication?

A balanced diet is recommended, with an appropriate increase in high-quality protein (fish, shrimp, eggs, soy products) and fresh fruits and vegetables. Avoid extreme dieting or overeating. No additional "fertility supplements" are needed unless recommended by your doctor.

Question 3: Do ovulation induction drugs have side effects?

Common side effects include bloating, breast tenderness, mood swings, and redness at the injection site. OHSS is the most serious complication to watch for, characterized by severe bloating, nausea, decreased urination, and rapid weight gain. Seek immediate medical attention if these occur.

Question 4: If one stimulation cycle is unsuccessful, should I change the protocol next time?

Not necessarily. The doctor will analyze the reasons based on the response data from the previous treatment (number of oocytes retrieved, embryo quality, transfer outcome, etc.). If the response was good but pregnancy did not occur, a protocol change may not be needed. If the response was poor or complications occurred, an adjustment is necessary.

Question 5: Does the male partner need to be involved in the medication protocol decision?

The male partner's semen quality affects the fertilization method and embryo culture strategy but does not directly influence the female's ovulation induction protocol. However, if semen quality is severely abnormal, it may be necessary to adjust the oocyte retrieval timing or use ICSI technology in advance.